Compare Fidelity National Information Servcs Inc (FIS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs GSK plc — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 5.2× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and GSK plc for 93 Days on average.
| FIS | GSK | |
|---|---|---|
Market Cap | $17.71B | $91.88B |
Volume | 9,047,825 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $67.94 | $61.18 |
52-Week Low | $32.44 | $43.24 |
Typical Hold Time | 88 Days | 93 Days |
Enterprise Value | $38.22B | $111.88B |
Dividend Yield | 5.13% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while profitability has improved significantly with net income margin reaching 27.65% in 2026 projections. Recent business developments include multiple core banking platform wins and new product launches, positioning the company for growth in financial technology modernization.
FIS presents a compelling value opportunity with strong analyst support (56.76% buy ratings) and a $47.15 consensus price target representing 37% upside. However, investors face risks from the company's elevated debt levels and inconsistent cash flow generation. The technical bearish signal and recent price weakness suggest potential near-term volatility despite fundamental improvements.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
